Follow TopoGEN on:
Dr. Muller has over 100 publications in the molecular biology, genetics and biochemistry of Cancer. He has presented his work at over 400 international and local scientific meetings and seminars over his 30 year career in Cancer Research. He is the Director of Cancer Consortium of Central Florida and held administrative positions in the Comprehensive Cancer Center at Ohio State University. He has also been a study section member for the National Cancer Institute, American Cancer Society and ad hoc reviewer for the National Science Foundation. Dr. Muller has a strong research focus on topoisomerases, DNA/protein interactions, DNA repair, gene silencing, chromatin structure, DNA replication, telomerase/telomere function and gene regulation. These attributes plus extensive entrepreneurial experience in science provide essential leadership for the SAB. Dr. Muller is the founder of TopoGEN, based on his pioneering research in the field of Topoisomerase biochemistry and molecular biology. He has a career H-Factor of 30.
Dr. Avvedimento has been active in research for more than 25 years. After medical school, he worked at the NIH and Columbia University in New York. His research centers on basic biochemistry and molecular/cell biology on hormone action, autoimmunity and gene regulation. He has published extensively in high profile journals, including Cell, Nature, New England Journal of Medicine and Science. He currently runs a large, well funded research lab at the University of Naples and has been involved in several University spin-off companies. Dr. Avvedimento provides oversight and consultation on the Autoimmune Disease Projects and works closely with our strategic partner, Prius, in Naples, Italy.
Dr. Feliciello is a well funded investigator who has published in high impact journals. His research focus is in the area of Cancer and Signaling. Dr. Feliciello has discovered a novel biomarker suitable for diagnosing bladder cancer (BladCanTM) and TopoGEN has acquired the IP rights to commercialize the findings and develop a diagnostic testing platform using urine sediments for non-invasive testing.
Dr. Insabato oversees a large pathology clinical practice affiliated with the University Hospital system. He specializes in urogenital cancers and has a well funded research team in this clinical area. Importantly, Dr. Insabato has access to large number of patients and archival patient material with documented and detailed clinical profiles (disease history, pathology data, disease course, therapeutic history, etc.). The Italian healthcare system is strongly state subsidized, which makes clinical-diagnostic trials cost effective.
Dr. Munro has extensive research experience in metallo-chemistry and organic chemistry as a synthetic chemist. He was recently awarded a Fulbright Fellowship to perform research in the US (2011-12). Dr. Munro has synthesized a series of novel gold containing compounds that target eukaryotic and prokaryotic topoisomerases. TopoGEN has invited his participation on the SAB as part of a licensing agreement to develop the compounds as novel anti-cancer agents. There is a strong IP position on these agents with multiple patents filed. Dr. Munro has submitted several of his compounds to NCI for evaluation with promising results. TopoGEN staff have evaluated the agents in mechanism-based assays and validated their activities.
Dr. Matarese discovered the role of Leptin (the obesity hormone that regulates food intake and metabolism) in immunity and is well known in the field. Dr. Matarese and his team have further elucidated a new mechanism of Leptin control of T-regulatory cells. He and his team have developed a cell based sensing platform that predicts the course of chronic autoimmune diseases that are a financial drain on the world healthcare system. TopoGEN scientists are collaborating with Dr. Matarese’s group to commercialize novel and powerful technology to address an unmet need in autoimmunity.
614-451-5810 